Cancer
Conditions
Interventions
Patients are asked to wear Garmin Vivofit 3 from the day before of the initiation of chemotherapy until 28 days after the initiation of chemotherapy. The removal of the device is depended on patient&#
s decision. After 29 days of main observational period, patients are asked to keep wearing the device for another 5 months as a follow-up. Patients can decide to un-wear the device for anytime in a fo
Sponsors
Tokyo Medical University of Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age of 20 to 75 2. Diagnosed as Cancer 3. Plan to receive a first-line chemotherapy 4. Inpatients at the time of enrollment 5. Able to use own smartphone 6. Able to understand and answer in Japanese 7. Written informed consent
Exclusion criteria
Exclusion criteria: 1. Clinically severe cognitive deficiency and memory disorder
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adherence of Wearable-device | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of Brief Fatigue Inventory scores at day 29 from baseline scores. MD Anderson Symptom Inventory CTCAE ver.4 Proportion of self-setting of wearable device. Relation on sleep between records from wearable device and patient-reported outcomes. | — |
Countries
Japan
Contacts
Public ContactTempei Miyaji
The University of Tokyo Department of Clinical Trial Data Management, Graduate School of Medicine
Outcome results
None listed